A Michigan company developing technologies that could lead to personalized medicine through genomics has closed a $7 million Series B funding round.

Swift Biosciences, an Ann Arbor-based firm working with next-generation gene sequencing, received the $7 million investment from lead investor Fletcher Spaght Ventures, along with Renaissance Venture Capital Fund, and Series A investors including the Mercury Fund, the Michigan Accelerator Fund, and several individual investors.

Swift is developing a proprietary line of genetic sample preparation products called Accel-NGS, which will work with the company's myT Primer mutation detection technology. The technology has both cancer research and diagnostic implications, and has been non-exclusively licensed to a global diagnostic company.